The first azoloazine-class representative brought to implementation in the medical industry was Triazavirin, an original Russian antiviral drug. Application results and their personal experience with using Triazavirin for socially significant infectious diseases (influenza, acute respiratory viral infections) were presented by symposium speakers.

The educational event was aimed to help the participants master the principles of choosing the optimal therapeutic tactics for acute respiratory infections and influenza in accordance with the National Clinical Guidelines, at determining the need, time and extent of the treatment with acute respiratory diseases, specifically in patients with a concomitant somatic pathology.

Other speakers of the symposium were:

Shestakova Irina (Moscow) with a report “Antiviral drugs for influenza and SARS from the perspective of evidence-based medicine”;

Leneva Irina (Moscow) with a report “Viral polymerase inhibitors - a new class of drugs for influenza”;

Lvov Nikolai (St. Petersburg) with a report "Nucleoside analogues in flu therapy: history, prospects and experience";

Tikhonova Elena (Krasnoyarsk) with a report "Clinical experience of etiotropic therapy with viral infections";

VereshchikovVladislav with a report "Treatment of influenza and SARS in patients with a burdened somatic background."

The conference was headed by Nikolai Lvov (St. Petersburg), Irina Leneva (Moscow) and Irina Shestakova (Moscow).

The symposium broadcast will be available for watching on November 21, 2018, 16:00 to 17:11 (Moscow time) on the website of Internist, the National Online Society of Internal Medicine Experts:

https://internist.ru/events/detail/34255/